

EVIDENCE CONCERNING HOSPITALIZATION

3 Studies after September 1, 2022

Section L(a) of the September 12, 2022 order states: “*the vaccines ... are highly effective in protecting against ... hospitalization ...*”

Section R of the September 12, 2022 order states: “*Vaccinated people ... have been shown to have high levels of protection against severe illness*”

1. A primary vaccination series provides little benefit against BA.4/BA.5 hospitalization.

Study: Collie, S., Nayager, J., Bamford, L. et al. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. *New England Journal of Medicine*, 387:1332-1333 (October 6th, 2022)

Findings:

- 19.3% effectiveness against BA.4/BA.5 hospitalization >9 months since ones 2nd dose of a primary series

Overall: a primary vaccination series provides little benefit against BA.4/BA.5 hospitalization, not “highly effective” or “high levels of protection” as referred to in the orders.

2. A primary vaccination series provides no benefit against BA.4/BA.5 hospitalization.

Study: Tartof, S., Slezak, J., Puzniak, L., et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. *The Lancet Infectious Diseases*. 22(12): 1663-1665 (December 1st, 2022)

Findings:

- A primary vaccination series was 0% effective against BA.4/BA.5 hospitalization 6 months after one’s 2nd dose

Overall: a primary vaccination series provides zero benefit against BA.4/BA.5 hospitalization, not “highly effective” or “high levels of protection” as referred to in the orders.

3. A primary vaccination series provides no benefit against BA.2 and BA.4 hospitalization.

Study: Kirsebom, F., Andrews, N., Stowe, J., et al. Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England. *The Lancet Regional Health Europe*. 23(100537) (November 10th, 2022)

Findings:

- A primary vaccination series was 0% effective against BA.2 and BA.4 hospitalization 6 months after one’s 2nd dose

Overall: a primary vaccination series provides zero benefit against BA.2 and BA.4 hospitalization, not “highly effective” or “high levels of protection” as referred to in the orders.